uniQure’s (QURE) “Buy” Rating Reiterated at Chardan Capital

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 197.34% from the company’s current price.

Other analysts have also issued reports about the stock. Wells Fargo & Company dropped their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Tuesday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Stock Up 4.3%

QURE opened at $12.78 on Monday. The business’s fifty day simple moving average is $12.22 and its 200 day simple moving average is $12.13. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock has a market cap of $700.04 million, a PE ratio of -2.58 and a beta of 0.10. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $5.93 million. As a group, research analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In other uniQure news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. The trade was a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This trade represents a 1.14% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. Franklin Resources Inc. bought a new stake in uniQure in the 3rd quarter worth approximately $7,360,000. FNY Investment Advisers LLC bought a new stake in uniQure in the 4th quarter worth approximately $88,000. Sanders Morris Harris LLC grew its position in uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares during the period. China Universal Asset Management Co. Ltd. grew its position in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the period. Finally, Palumbo Wealth Management LLC bought a new stake in uniQure in the 4th quarter worth approximately $437,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.